AZD-8931 is an inhibitor of EGFR, HER2, and HER3 that exhibits anticancer chemotherapeutic activity. In vitro and in vivo, AZD-8931 suppresses growth of inflammatory breast cancer cells and tumors and induces apoptosis. This compound also inhibits growth in cellular models of non-small cell lung cancer (NSCLC) and squamous cell carcinoma.
| Cas No. | 848942-61-0 |
|---|---|
| Purity | ≥98% |
| Formula | C23H25ClFN5O3 |
| Formula Wt. | 473.93 |
| IUPAC Name | 2-[4-({4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl}oxy)-1-piperidinyl]-N-methylacetamide |
| Synonym | AZD8931, Sapitinib |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | A9813 Info Sheet PDF |
|---|
Mu Z, Klinowska T, Dong X, et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. J Exp Clin Cancer Res. 2014 May 30;33:47. PMID: 24886365.
Tjulandin S, Moiseyenko V, Semiglazov V, et al. Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. Invest New Drugs. 2014 Feb;32(1):145-53. PMID: 23589215.
Hickinson DM, Klinowska T, Speake G, et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res. 2010 Feb 15;16(4):1159-69. PMID: 20145185.
